Roswell R&D Tax Credit Benefits for Your Business

R&D Tax Credits for Roswell, Georgia Businesses

Roswell, Georgia, is home to top R&D companies like Hewlett Packard Enterprise, Kimberly-Clark, Fiserv, McKesson, and Roswell Park Cancer Institute’s research programs. These organizations specialize in technology, healthcare, and consumer goods innovation. The R&D tax credit allows them to offset a portion of their research expenses, reducing their tax burden. By reinvesting these savings into further innovation, workforce development, or infrastructure, these companies can enhance their competitiveness, drive growth, and contribute to Roswell’s economic development.

Find out more

Are you eligible?

Why choose us?

Pass an Audit?

Swanson Reed is one of the only companies in the United States to exclusively focus on R&D tax credit preparation. Swanson Reed’s office location at 400 West Peachtree Street NW, Atlanta, Georgia is less than 25 miles away from Roswell and provides R&D tax credit consulting and advisory services to Roswell and the surrounding areas such as: Atlanta, Sandy Springs, South Fulton, Johns Creek and Marietta.

If you have any questions or need further assistance, please call or email our local Georgia Partner on (404) 448-1354.
Feel free to book a quick teleconference with one of our Georgia R&D tax credit specialists at a time that is convenient for you. Click here for more information about R&D tax credit management and implementation.

Schedule a Teleconference

Roswell, Georgia Patent of the Year – 2024/2025

CorMatrix Cardiovascular Inc. has been awarded the 2024/2025 Patent of the Year for its groundbreaking innovation in cardiovascular tissue repair. Their invention, detailed in U.S. Patent No. 11865226, titled ‘Cardiovascular prostheses’, utilizes a novel biomaterial composed of poly(glycerol sebacate) (PGS), cerivastatin, and everolimus to modulate inflammation and promote healing in damaged heart tissue.

This patented prosthesis introduces particulate structures designed to increase the expression of Kruppel-like factor 2 (KLF-2), a gene that plays a critical role in vascular health. By enhancing KLF-2 expression, the device effectively reduces the production of inflammatory markers such as MCP-1 and CCR2, leading to a decrease in tissue inflammation and improved healing outcomes.

The innovation addresses a significant challenge in cardiovascular medicine: the body’s inflammatory response to implanted devices. Traditional prostheses can trigger adverse reactions, compromising their effectiveness. CorMatrix’s approach offers a biocompatible solution that not only supports tissue regeneration but also minimizes inflammation, potentially improving patient recovery and long-term outcomes.

This advancement exemplifies the ongoing evolution of biomaterials in medical applications, highlighting the potential for engineered solutions to enhance the body’s natural healing processes. As cardiovascular diseases remain a leading cause of mortality worldwide, innovations like this represent a promising step forward in patient care and medical technology.